Pulmonary Embolism Market Growth Analysis 2025 To 2032

Posted 2026-02-12 04:17:54

Market Overview:

The Pulmonary Embolism (PE) market is concerned with the diagnosis and treatment of pulmonary embolism, a life-threatening condition where a blood clot blocks a pulmonary artery in the lungs. The market includes various diagnostic techniques such as imaging technologies such as CT pulmonary angiography (CTPA), ventilation-perfusion scans (V/Q), and D-dimer tests. The treatment options include anticoagulants, thrombolytics, and surgical interventions such as embolectomy. The market is driven by the rising awareness of PE, the improvement in diagnostic tools, and the development of newer anticoagulant therapies that are safer and more effective.

Key players:

Bayer AG, BristolMyers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Johnson Johnson, Pfizer Inc, Sanofi, GlaxoSmithKline plc, Novartis AG, AstraZeneca, Merck Co Inc, Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, F HoffmannLa Roche Ltd, AbbVie Inc, Abbott Laboratories, Mylan NV, Amgen Inc, Takeda Pharmaceutical Company Limited, Novo Nordisk AS

Sample Link- https://www.trendbridgeinsights.com/industry-report/pulmonary-embolism-market

Market segmentation:

Product Type

Anticoagulants
Thrombolytics
Inferior Vena Cava Filters
Compression Stockings

Diagnosis Type

CT Pulmonary Angiography CTPA
VentilationPerfusion VQ Scan
DDimer Test
Echocardiography

Treatment Type

Medication
Surgical Procedures
Catheterdirected Therapy
Embolectomy

End User

Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Diagnostic Centers

Mega Trend Connect:

This report offers deep insights into how mega trends such as digitalization, precision medicine, data-driven care delivery, and regulatory evolution are transforming pharmaceuticals. It further examines the impact of advanced technologies, platform-based models, automation, and interoperability across products and services within this segment. The report assesses regulatory complexity, adoption readiness, cost pressures, and ecosystem maturity shaping global market development.

Global Trade Outlook:

Global trade in pharmaceuticals is increasingly shaped by regulatory stringency, localization mandates, data sovereignty requirements, and public health policy priorities. Cross-border scalability is constrained by approval timelines, compliance variation, and infrastructure readiness, driving regionalized production, partnerships, and delivery models. Market access and competitiveness now depend on regulatory agility, localized execution, and compliance-by-design strategies.

Region Analysis:

North America leads the Pulmonary Embolism (PE) market due to high risk factors, advanced healthcare, and broad access to anticoagulants, thrombolytics, and surgical care. Europe holds strong share through early detection, effective management, and robust regulatory systems. Asia-Pacific grows rapidly as China, India, Japan, and South Korea face rising cardiovascular risks and expand healthcare capacity. MEA grows steadily with improving infrastructure, higher chronic disease rates, and strong medical tourism in the UAE.

Recent Developments:

In April 2023, Dr. Reddy’s Laboratories Ltd launched a generic version of Treprostinil for treating pulmonary arterial hypertension that leads to PE. The product provides patients with an affordable treatment option.

F&Q:

Q1. What is the projected market size & growth rate of the Pulmonary Embolism Market?

Pulmonary Embolism Market was valued at USD 3.6 billion in 2024 and is expected to reach to USD 6.2 billion by 2032, growing at a CAGR of 6.8% from 2025 to 2032.

Q2. What are the key driving factors for the growth of the Pulmonary Embolism Market?

Pulmonary Embolism Market is driven by Rising Prevalence of Risk Factors, Increased Awareness of Pulmonary Embolism, Growing Adoption of Anticoagulants and Thrombolytics, High Treatment Costs, Limited Access to Diagnostic Tools in Emerging Markets, Complications with Long-Term Treatment, Emerging Markets for PE Diagnosis and Treatment, Development of Safer, More Effective Therapies, Telemedicine and Remote Monitoring, Limited Availability of Trained Healthcare Providers, Underdiagnosis and Misdiagnosis, Risk of Recurrence and Long-Term Complications.

Q3. What are the top players operating in the Pulmonary Embolism Market?

The major players in the market are Bayer AG, BristolMyers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Johnson Johnson, Pfizer Inc, Sanofi, GlaxoSmithKline plc, Novartis AG, AstraZeneca, Merck Co Inc, Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, F HoffmannLa Roche Ltd, AbbVie Inc, Abbott Laboratories, Mylan NV, Amgen Inc, Takeda Pharmaceutical Company Limited, Novo Nordisk AS

Q4. What segments are covered in the Pulmonary Embolism Market?

The Global Pulmonary Embolism Market is segmented based on Product Type, Diagnosis Type, Treatment Type, End User, and Geography.

About US: